<SEC-DOCUMENT>0001193125-22-233468.txt : 20220830
<SEC-HEADER>0001193125-22-233468.hdr.sgml : 20220830
<ACCEPTANCE-DATETIME>20220830080103
ACCESSION NUMBER:		0001193125-22-233468
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220826
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220830
DATE AS OF CHANGE:		20220830

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CURIS INC
		CENTRAL INDEX KEY:			0001108205
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				043505116
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30347
		FILM NUMBER:		221212914

	BUSINESS ADDRESS:	
		STREET 1:		128 SPRING STREET
		STREET 2:		BUILDING C, SUITE 500
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		617-503-6500

	MAIL ADDRESS:	
		STREET 1:		128 SPRING STREET
		STREET 2:		BUILDING C, SUITE 500
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d397699d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cris="http://www.curis.com/20220826" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2022-08-26_to_2022-08-26">CURIS INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-08-26_to_2022-08-26">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-08-26_to_2022-08-26">0001108205</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="cris-20220826.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-08-26_to_2022-08-26"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-26</xbrli:startDate> <xbrli:endDate>2022-08-26</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-08-26_to_2022-08-26">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-08-26_to_2022-08-26" format="ixt:datemonthdayyearen">August&#160;26, 2022</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">Curis, Inc.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-08-26_to_2022-08-26" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-08-26_to_2022-08-26">000-30347</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-08-26_to_2022-08-26">04-3505116</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or Other Jurisdiction<br />of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(I.R.S. Employer<br />Identification Number)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-08-26_to_2022-08-26">128 Spring Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2022-08-26_to_2022-08-26">Building C - Suite 500</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-08-26_to_2022-08-26">Lexington</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-08-26_to_2022-08-26">MA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-08-26_to_2022-08-26">02421</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of Principal Executive Offices) (Zip Code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-08-26_to_2022-08-26">(617)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-08-26_to_2022-08-26">503-6500</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-08-26_to_2022-08-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-08-26_to_2022-08-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-08-26_to_2022-08-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-08-26_to_2022-08-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-08-26_to_2022-08-26">Common Stock, Par Value $0.01 per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-08-26_to_2022-08-26">CRIS</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-08-26_to_2022-08-26" format="ixt-sec:exchnameen">Nasdaq Global Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-08-26_to_2022-08-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;30, 2022, Curis, Inc. (&#8220;Curis&#8221; or the &#8220;Company&#8221;) issued a press release announcing that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) has notified Curis that it may resume enrollment of additional patients in the monotherapy dose finding phase (&#8220;Phase 1a&#8221;) of the Company&#8217;s TakeAim Leukemia Phase 1/2 study (NCT04278768) of emavusertib <span style="white-space:nowrap">(CA-4948)</span> after reviewing the comprehensive data package submitted by the Company. The partial hold remains in place for the combination therapy phase (&#8220;Phase 1b&#8221;) and the expansion phase (&#8220;Phase 2a&#8221;) of the TakeAim Leukemia study until Phase 1a is complete and the FDA approves proceeding to the next phases of the study. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cautionary Note Regarding Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, any statements with respect to Curis&#8217;s plans, strategies and objectives to resume and further patient enrollment in its TakeAim Lymphoma trial and in the monotherapy doses escalation phase (Phase 1a) of the TakeAim Leukemia trial, and its ability to resolve the remaining partial clinical hold on the combination therapy phase (Phase1b) and the expansion phase (Phase 2a) of the TakeAim Leukemia study, statements concerning product research, development, clinical trials and studies and commercialization plans, timelines, anticipated results or the therapeutic potential of drug candidates including any statements regarding the initiation, progression, expansion, use, safety, efficacy, dosage and potential benefits of emavusertib in clinical trials as a monotherapy and/or as a combination therapy, Curis&#8217;s plans and timelines to provide preliminary, interim and/or additional data from its ongoing or planned clinical trials, any statements concerning Curis&#8217;s expectations regarding its interactions with the FDA, statements with respect to mutations or potential biomarkers, and statements of assumptions underlying any of the foregoing. Forward-looking statements may contain the words &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;assumes,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;targets,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;focus,&#8221; &#8220;strategy,&#8221; &#8220;mission,&#8221; or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements. For example, the FDA may not remove the remaining partial clinical hold on the combination therapy phase (Phase 1b) and the expansion phase (Phase 2a) of Phase 1/2 TakeAim Leukemia trial, or may take further regulatory action with regard to such trial. Curis may experience adverse results, delays and/or failures in its drug development programs and may not be able to successfully advance the development of its drug candidates in the time frames it projects, if at all. Curis&#8217;s drug candidates may cause unexpected toxicities, fail to demonstrate sufficient safety and efficacy in clinical studies and/or may never achieve the requisite regulatory approvals needed for commercialization. Favorable results seen in preclinical studies and early clinical trials of Curis&#8217;s drug candidates may not be replicated in later trials. There can be no guarantee that the collaboration agreements with Aurigene and ImmuNext, or the CRADA with NCI, will continue for their full terms, that Curis or its collaborators will each maintain the financial and other resources necessary to continue financing its portion of the research, development and commercialization costs, or that the parties will successfully discover, develop or commercialize drug candidates under the collaboration. Regulatory authorities may determine to delay or restrict Genentech&#8217;s and/or Roche&#8217;s ability to continue to develop or commercialize Erivedge in BCC. Erivedge may not demonstrate sufficient or any activity to merit its further development in disease indications other than BCC. Competing drugs may be developed that are superior to Erivedge. In connection with its agreement with Oberland Capital, Curis faces risks relating to the transfer and encumbrance of certain royalty and royalty-related payments on commercial sales of Erivedge, including the risk that, in the event of a default by Curis or its wholly-owned subsidiary, Curis could lose all retained rights to future royalty and royalty-related payments, Curis could be required to repurchase such future royalty and royalty-related payments at a price that is a multiple of the payments it has received, and its ability to enter into future arrangements may be inhibited, all of which could have a material adverse effect on its business, financial condition and stock price. Curis will require substantial additional capital to fund its business. If it is not able to obtain sufficient </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
funding, it will be forced to delay, reduce in scope or eliminate some of its research and development programs, including related clinical trials and operating expenses, potentially delaying the time to market for, or preventing the marketing of, any of its product candidates, which could adversely affect its business prospects and its ability to continue operations, and would have a negative impact on its financial condition and its ability to pursue its business strategies. Curis faces substantial competition. Curis and its collaborators face the risk of potential adverse decisions made by the FDA and other regulatory authorities, investigational review boards, and publication review bodies. Curis may not obtain or maintain necessary patent protection and could become involved in expensive and time-consuming patent litigation and interference proceedings. Unstable market and economic conditions, natural disasters, public health crises, political crises and other events outside of Curis&#8217;s control could significantly disrupt its operations or the operations of third parties on which Curis depends, and could adversely impact Curis&#8217;s operating results and its ability to raise capital. For example, the <span style="white-space:nowrap">COVID-19</span> pandemic may result in closures of third-party facilities, impact enrollment in clinical trials or impact sales of Erivedge by Genentech and/or Roche. The extent to which the <span style="white-space:nowrap">COVID-19</span> pandemic may impact Curis&#8217;s business or operating results is uncertain. Other important factors that may cause or contribute to actual results being materially different from those indicated by forward-looking statements include the factors set forth under the captions &#8220;Risk Factor Summary&#8221; and &#8220;Risk Factors&#8221; in our most recent Form <span style="white-space:nowrap">10-K</span> and Form <span style="white-space:nowrap">10-Q,</span> and the factors that are discussed in other filings that we periodically make with the Securities and Exchange Commission. In addition, any forward-looking statements represent the views of Curis only as of today and should not be relied upon as representing Curis&#8217;s views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this Current Report on Form <span style="white-space:nowrap">8-K</span> whether as a result of new information, future events or otherwise, except as may be required by law. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d397699dex991.htm">Press Release dated August&#160;30, 2022 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">Curis, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: August&#160;30, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Diantha Duvall</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Diantha Duvall</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d397699dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g397699g0830065309961.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRESS RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FDA Allows Patient Enrollment to Resume in Monotherapy Dose </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Escalation of Emavusertib in TakeAim Leukemia Study </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Curis working with clinical sites to resume enrollment </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Preliminary clinical data update expected in 2023 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LEXINGTON, Mass., August&nbsp;30, 2022 /PRNewswire/ &#151; Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative
therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has notified Curis that it may resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Previously, Curis announced that the FDA had placed partial clinical holds on the TakeAim Leukemia and TakeAim Lymphoma studies in April 2022. On
August&nbsp;18, 2022, Curis reported that the partial clinical hold on the TakeAim Lymphoma study was lifted. After review of the comprehensive data package submitted by Curis, the FDA has notified Curis that it may resume enrollment of additional
patients in the monotherapy dose finding phase (Phase 1a) of the TakeAim Leukemia study, in which the company has agreed to enroll at least nine additional patients at the 200mg dose level. The partial hold remains in place for the combination
therapy phase (Phase 1b) and the expansion phase (Phase 2a) of the study until Phase 1a is complete and the FDA approves proceeding to the next phases of the study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before lifting the restriction on patient enrollment, the FDA reviewed additional data provided by the company related to the risk of rhabdomyolysis, a side
effect also associated with statins, as well as with cancer medications such as Odomzo<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and Cotellic<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. The FDA also reviewed the
company&#146;s strategy for utilizing objective laboratory measurements, similar to those used with Odomzo and Cotellic, to identify rhabdomyolysis, as well as the company&#146;s strategy for managing rhabdomyolysis, if it is detected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased to announce the results of the FDA&#146;s review and to have addressed potential concerns about the identification and management of
rhabdomyolysis,&#148; said James Dentzer, President and Chief Executive Officer of Curis. &#147;We are working with our clinical sites to quickly resume enrollment of additional patients.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similar to the TakeAim Lymphoma study, the Company is updating its timeline for clinical data release to
reflect the availability of updated preliminary data from the TakeAim Leukemia study in 2023. In addition, Curis is proactively discussing the clinical plans for emavusertib in leukemia, including alignment on optimal dose and development path, with
the FDA&#146;s leukemia division. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Emavusertib <FONT STYLE="white-space:nowrap">(CA-4948)</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emavusertib is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor (TLR) and
<FONT STYLE="white-space:nowrap">interleukin-1</FONT> receptor <FONT STYLE="white-space:nowrap">(IL-1R)</FONT> signaling pathways, which are frequently dysregulated in patients with cancer. TLRs and the <FONT STYLE="white-space:nowrap">IL-1R</FONT>
family signal through the adaptor protein MYD88, which results in the assembly and activation of IRAK4, initiating a signaling cascade that induces cytokine and survival factor expression mediated by the NF-<SMALL>K</SMALL>B protein complex.
Additionally, third parties have recently discovered that the long form of IRAK4 <FONT STYLE="white-space:nowrap">(IRAK4-L)</FONT> is oncogenic and preferentially expressed in over half of patients with acute myeloid leukemia (AML) and
myelodysplastic syndrome (MDS). The overexpression of <FONT STYLE="white-space:nowrap">IRAK4-L</FONT> is believed to be driven by a variety of factors, including specific spliceosome mutations such as SF3B1 and U2AF1. In addition to inhibiting
IRAK4, emavusertib was also designed to inhibit FLT3, a known oncologic driver, which may provide additional benefit in patients with AML and MDS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About TakeAim Leukemia </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The TakeAim Leukemia study
(NCT04278768) is a Phase 1/2 open-label dose escalation, dose expansion clinical trial investigating emavusertib as a monotherapy and in combination with azacitidine or venetoclax in patients with relapsed or refractory (R/R) AML or high risk MDS.
After dose escalation in monotherapy to determine the recommended Phase 2 dose (RP2D) and assuming the partial hold for the phase 1b cohort dose escalation in combination to determine the RP2D is lifted, we plan to expand five cohorts: monotherapy
in AML patients with spliceosome and FLT3 mutations, monotherapy in patients with MDS and spliceosome mutations and combination therapy with azacitidine or venetoclax in patients without spliceosome or FLT3 mutations. The goals of the study are to
determine several parameters including safety, maximum tolerated dose (MTD), RP2D and signals of activity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About TakeAim Lymphoma </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The TakeAim Lymphoma study (NCT03328078) is a Phase 1/2 open-label, dose escalation, dose expansion clinical trial investigating emavusertib as monotherapy and
in combination with ibrutinib in patients with R/R hematologic malignancies, such as <FONT STYLE="white-space:nowrap">non-Hodgkin&#146;s</FONT> lymphoma and other B cell malignancies. After dose escalation in both monotherapy and combination therapy
to determine the RP2D, we plan to expand four cohorts for combination treatment: marginal zone lymphoma, activated <FONT STYLE="white-space:nowrap">b-cell</FONT> diffuse large <FONT STYLE="white-space:nowrap">b-cell</FONT> lymphoma, primary CNS
lymphoma, and patients developing adaptive resistance to ibrutinib monotherapy. The goals of the study are to determine several parameters including safety, MTD, RP2D and signals of activity. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Curis, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration
with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist <FONT
STYLE="white-space:nowrap">CA-170,</FONT> and the TIM3/PDL1 antagonist <FONT STYLE="white-space:nowrap">CA-327,</FONT> as well as the IRAK4 kinase inhibitor, emavusertib <FONT STYLE="white-space:nowrap">(CA-4948).</FONT> Emavusertib is currently
undergoing testing in the Phase 1/2 TakeAim Lymphoma trial, in patients with hematologic malignancies, such as <FONT STYLE="white-space:nowrap">non-Hodgkin&#146;s</FONT> lymphoma and other B cell malignancies, both as a monotherapy and in
combination with BTK inhibitor ibrutinib, and the Phase 1/2 TakeAim Leukemia trial in patients with AML and MDS, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. The FDA has placed a partial clinical hold
on the TakeAim Leukemia trial during which no new patients will be enrolled in the combination phase (Phase 1b) of emavusertib with azacitidine or venetoclax and expansion phase (Phase 2a), and current study participants benefiting from treatment
may continue to be treated with emavusertib at doses of 300mg BID or lower. In addition, Curis is engaged in a collaboration with ImmuNext for development of <FONT STYLE="white-space:nowrap">CI-8993,</FONT> a monoclonal anti-VISTA antibody, which is
currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> for the treatment of advanced basal cell carcinoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, visit Curis&#146;s
website at www.curis.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, without
limitation, any statements with respect to Curis&#146;s plans, strategies and objectives to resume and further patient enrollment in its TakeAim Lymphoma trial and in the monotherapy dose escalation phase (Phase 1a) of the TakeAim Leukemia trial,
and its ability to resolve the remaining partial clinical hold on the combination therapy phase (Phase 1b) and the expansion phase (Phase 2a) of the TakeAim Leukemia study, statements concerning product research, development, clinical trials and
studies and commercialization plans, timelines, anticipated results or the therapeutic potential of drug candidates including any statements regarding the initiation, progression, expansion, use, safety, efficacy, dosage and potential benefits of
emavusertib in clinical trials as a monotherapy and/or as a combination therapy, Curis&#146;s plans and timelines to provide preliminary, interim and/or additional data from its ongoing or planned clinical trials, any statements concerning
Curis&#146;s expectations regarding its interactions with the FDA, statements with respect to mutations or potential biomarkers, and statements of assumptions underlying any of the foregoing. Forward-looking statements may contain the words
&#147;believes,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;plans,&#148; &#147;intends,&#148; &#147;seeks,&#148; &#147;estimates,&#148; &#147;assumes,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;targets,&#148;
&#147;will,&#148; &#147;may,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148; &#147;continue,&#148; &#147;potential,&#148; &#147;focus,&#148; &#147;strategy,&#148; &#147;mission,&#148; or similar expressions. These forward-looking
statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements. For
example, the FDA may not remove the remaining partial clinical hold on the combination therapy phase (Phase 1b) and the expansion phase (Phase 2a) of TakeAim Leukemia trial, or may take further regulatory action with regard to such trial. Curis may
experience adverse results, delays and/or failures in its drug development programs and may not be able to successfully advance the development of its drug candidates in the time frames it projects, if at all. Curis&#146;s drug candidates may cause
unexpected toxicities, fail to demonstrate sufficient safety and efficacy in clinical studies and/or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may never achieve the requisite regulatory approvals needed for commercialization. Favorable results seen in preclinical studies and early clinical trials of Curis&#146;s drug candidates may not
be replicated in later trials. There can be no guarantee that the collaboration agreements with Aurigene and ImmuNext will continue for their full terms, or the CRADA with NCI, that Curis or its collaborators will each maintain the financial and
other resources necessary to continue financing its portion of the research, development and commercialization costs, or that the parties will successfully discover, develop or commercialize drug candidates under the collaboration. Regulatory
authorities may determine to delay or restrict Genentech&#146;s and/or Roche&#146;s ability to continue to develop or commercialize Erivedge in basal cell carcinoma (BCC). Erivedge may not demonstrate sufficient or any activity to merit its further
development in disease indications other than BCC. Competing drugs may be developed that are superior to Erivedge. In connection with its agreement with Oberland Capital, Curis faces risks relating to the transfer and encumbrance of certain royalty
and royalty-related payments on commercial sales of Erivedge, including the risk that, in the event of a default by Curis or its wholly-owned subsidiary, Curis could lose all retained rights to future royalty and royalty-related payments, Curis
could be required to repurchase such future royalty and royalty-related payments at a price that is a multiple of the payments it has received, and its ability to enter into future arrangements may be inhibited, all of which could have a material
adverse effect on its business, financial condition and stock price. Curis will require substantial additional capital to fund its business. If it is not able to obtain sufficient funding, it will be forced to delay, reduce in scope or eliminate
some of its research and development programs, including related clinical trials and operating expenses, potentially delaying the time to market for, or preventing the marketing of, any of its product candidates, which could adversely affect its
business prospects and its ability to continue operations, and would have a negative impact on its financial condition and its ability to pursue its business strategies.&nbsp;Curis faces substantial competition. Curis and its collaborators face the
risk of potential adverse decisions made by the FDA and other regulatory authorities, investigational review boards, and publication review bodies. Curis may not obtain or maintain necessary patent protection and could become involved in expensive
and time-consuming patent litigation and interference proceedings. Unstable market and economic conditions, natural disasters, public health crises, political crises and other events outside of Curis&#146;s control could significantly disrupt its
operations or the operations of third parties on which Curis depends and could adversely impact Curis&#146;s operating results and its ability to raise capital. For example, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may result in
closures of third-party facilities, impact enrollment in clinical trials or impact sales of Erivedge by Genentech&nbsp;and/or Roche.&nbsp;The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may impact Curis&#146;s
business or operating results is uncertain. Other important factors that may cause or contribute to&nbsp;actual results being materially different from those indicated by forward-looking statements include the factors set forth under the captions
&#147;Risk Factor Summary&#148; and &#147;Risk Factors&#148; in our most recent Form <FONT STYLE="white-space:nowrap">10-K</FONT> and Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> and the factors that are discussed in other filings that we
periodically make with the Securities and Exchange Commission (&#147;SEC&#148;). In addition, any forward-looking statements represent the views of Curis only as of today and should not be relied upon as representing Curis&#146;s views as of any
subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by
law.<B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Craig West
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VP, Investor Relations&nbsp;&amp; Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-503-6507</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cwest@curis.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cris-20220826.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 8/30/2022 2:58:48 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:cris="http://www.curis.com/20220826"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.curis.com/20220826"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cris-20220826_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cris-20220826_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cris-20220826_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 8/30/2022 2:58:48 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cris-20220826_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 8/30/2022 2:58:48 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cris-20220826.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g397699g0830065309961.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g397699g0830065309961.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] '4# 2(  A$! Q$!_\0
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MR6#Q!]'_ /0J]3KRKPJ<?&/7AZA_YBO5:WQ/Q+T1S83X'ZLS/$7_ "+>I?\
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)TZ***YSJ/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140020314968608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CURIS INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001108205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 26,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3505116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">128 Spring Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building C - Suite 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lexington<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">503-6500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, Par Value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRIS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d397699d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cris-20220826.xsd" xlink:type="simple"/>
    <context id="duration_2022-08-26_to_2022-08-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <startDate>2022-08-26</startDate>
            <endDate>2022-08-26</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2022-08-26_to_2022-08-26"
      id="Hidden_dei_EntityRegistrantName">CURIS INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2022-08-26_to_2022-08-26">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-08-26_to_2022-08-26"
      id="Hidden_dei_EntityCentralIndexKey">0001108205</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-08-26_to_2022-08-26">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-08-26_to_2022-08-26">2022-08-26</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-08-26_to_2022-08-26">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-08-26_to_2022-08-26">000-30347</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-08-26_to_2022-08-26">04-3505116</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-08-26_to_2022-08-26">128 Spring Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2022-08-26_to_2022-08-26">Building C - Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-08-26_to_2022-08-26">Lexington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-08-26_to_2022-08-26">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-08-26_to_2022-08-26">02421</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-08-26_to_2022-08-26">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-08-26_to_2022-08-26">503-6500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-08-26_to_2022-08-26">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-08-26_to_2022-08-26">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-08-26_to_2022-08-26">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-08-26_to_2022-08-26">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-08-26_to_2022-08-26">Common Stock, Par Value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-08-26_to_2022-08-26">CRIS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-08-26_to_2022-08-26">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-08-26_to_2022-08-26">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M@CRS.CYT!H)8)>6WV!\"<4H'?NC "^[R107EM;!B/#1Z1XQ[&M3<13'4HC?
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M/#_)Y6]B:38N2G^!@MVZ*9B*I/$,T")X=*;Y;\Z_[K^$>^'>F)%(KD&(GE^
MKBF/YV7#ZK0X$J^TA0-V<;F5 E:!>P!^7VMM7QONE%W]23+^'U!+ P04
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MJ'7N0;#W\!J-'<V/'[?\ 5!+ P04    "  A0!Y5)!Z;HJT   #X 0  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,
M75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO
M *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR
M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/
M3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ (4 >5660>9(9 0  SP,
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +
M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5
M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP
M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM
M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>
M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]
M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M"  A0!Y5!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( "% 'E4=9S;([0   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( "% 'E697)PC
M$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ (4 >58PF]-Y>!   ,!$  !@              ("!# @
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( "% 'E6?H!OP
ML0(  .(,   -              "  : ,  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ (4 >59>*NQS     $P(   L              ( !? \  %]R96QS
M+RYR96QS4$L! A0#%     @ (4 >51PX9>H_ 0  / (   \
M ( !91   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "% 'E4D'INBK0
M /@!   :              "  =$1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( "% 'E5ED'F2&0$  ,\#   3              "
M ;82  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(    4
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d397699d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName -  d397699d8k.htm 7</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="d397699d8k.htm">d397699d8k.htm</File>
    <File>cris-20220826.xsd</File>
    <File>cris-20220826_lab.xml</File>
    <File>cris-20220826_pre.xml</File>
    <File>d397699dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d397699d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d397699d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cris-20220826_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cris-20220826_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cris-20220826.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cris",
   "nsuri": "http://www.curis.com/20220826",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d397699d8k.htm",
      "contextRef": "duration_2022-08-26_to_2022-08-26",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d397699d8k.htm",
      "contextRef": "duration_2022-08-26_to_2022-08-26",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com//20220826/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-22-233468-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-233468-xbrl.zip
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M6949NV"EM\PO:V2DE)(66BF2 ?3_<8\P5(D@<2O@G+M9!/62D)X\'>7I03[
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M(Q^8;<=UMWVU^AEFFT/<W0R'O;UJEPW]_ ]02P,$%     @ (4 >5:GF"<J
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M(L*D=0VJV6">^?:AD8C[I$,]L@X^U[&=,L8.1I$_/SSPY1W3R3P0'QJ^U''
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M1FJPGD2$/D@]B4#PTS1(>"BB5 =SI@$_]'A.(]@'HA'PRP1>M@2O\F)<"OV
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M#Q.?V95%;L?' I&@U1!DJF'-*(,MQ ^4&'I-G=**B\*A'=5M=EJM6E 2Y>S
M7#H?072'NC'D,627@0V8T47B7CITKU@.X4FAAF->W4RGF7Q\77@Z'2F"55!
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MOEHWX3CHF)]SIQ][/_Q_4$L#!!0    ( "% 'E73_YJ3&A<  .=*   1
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MDZJ.543MD>:K0H=W232 JD8+07.)4Z&0618KED8(+NTE0DA=V#PNC"CVO;%
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M]9%S2=_9I$-D2I;*7/B4-YPC-%W2E)6,82Z /Q\PSKN[>WL[=<1@NXX2[DB
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MO(&($<L5+MJ]](62( OW+61Z\I,:[K&W-L&>=^!;;@44_E]"J+]=_7.L+M%
M([2!A$5UT#<_H7'34U=?UJ1A* ISLWW:5"^<9[/=NND;>L_O:MT\,;>11"-5
M8: JE_0 ]VE@=BT]I]#-NZ;P]DZ^,K@IQ[3[Y;MD9(@+]^3^1XHW)4WH\L)_
M.4!F.7Y>/UN;W1^:ZR-?_-2_%K9.6L(G=.P_=/(?$+"J!I:^N/#W3!'5&#^3
M2$GB8^H75?WGQDR+7G'V   'D$3PW#<0U;H(Y.;L1.3P8FX.+EM*CRH)L) P
M0RI5&87TNGI&)*&<*[[G_]4"Q"GND8:^$;7TP5TYH<C;.(Y>TPHK<K0<!IH
M6Y $Y0,;ZOA7R(LDEFC+':H9!_)4RDZX L+OL%J4]O\.1;MM_AB;FO<MN8]%
M#X5%I_8P<CHRK"&>=O@8A#MIV:(U\O6(-43W3!0[M324,0_T+1+OJ@J&K3!X
M'SPG>MH[.)9OM[[%+)CB<F@^-EC8_Q;?(IP@1PS5S\ 4U%M[[%5?I1?UTR?:
M"23X0C';R"PTEQ#W';+2&SA,-G%</9/KE&E5^/[%E'W! MNSD>;5UNONR\V=
M[JN7FZ]]P*F_ ?Q+J8^F$.G_5.L+3S1*84]7I[_@(O\#5_\/4$L! A0#%
M  @ (4 >5:(JII!" P  2@L  !$              ( !     &-R:7,M,C R
M,C X,C8N>'-D4$L! A0#%     @ (4 >5:GF"<J !@  ND8  !4
M     ( !<0,  &-R:7,M,C R,C X,C9?;&%B+GAM;%!+ 0(4 Q0    ( "%
M'E7&8@1FQ@0  #HL   5              "  20*  !C<FES+3(P,C(P.#(V
M7W!R92YX;6Q02P$"% ,4    "  A0!Y58M1$6@<9  !4@0  #@
M    @ $=#P  9#,Y-S8Y.60X:RYH=&U02P$"% ,4    "  A0!Y5T_^:DQH7
M  #G2@  $0              @ %0*   9#,Y-S8Y.61E>#DY,2YH=&U02P4&
2      4 !0!  0  F3\

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
